Thursday, July 16, 2026 Never miss a recall or a rule change Go Pro · $20/mo →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
FDA CLEAREDEasyWhip Family — Winter Innovations, Inc.2 weeks agoFDA CLEAREDLED Neck Beauty Mask (ZLD-66A,ZLD-90E,ZLD-130,ZLD-180H) — Shenzhen Kaiyan Medical Equipment Co., Ltd.4 weeks agoFDA CLEAREDLUTRONIC GENIUS — Cynosure Lutronic Technology Corporation2 weeks agoFDA CLEAREDPICOSURE WORKSTATION — Cynosure, LLC4 weeks agoFDA CLEAREDLED Light Therapy Masks (LED Face Mask Pro FAC08NA, LED Chest Mask Pro FAC09NA) — Guangdong Newdermo Biotech Co., Ltd.2 weeks agoFDA CLEAREDCoolSeal Generator® (CSL-200-90) — Hologic, Inc.4 weeks agoFDA CLEAREDHemolase Fiber (Hemo-R-0.40-2.5/Hemo-R-0.60-2.5/Hemo-R-0.40-1.8/Hemo-R-0.60-1.8) — Micro-Energy Medical Technology Co., Ltd.4 weeks agoFDA CLEAREDLED Light Therapy Mask (K9C-TK, K9C-K, K9P-YK, K9P-K, FM-03BK, FM-09K) — Guangdong Newdermo Biotech Co., Ltd.4 weeks ago
1 free article left this week. A free account gets you 4 a week.Go Pro →
Regulatory

Medicare Begins Price Negotiation for Botox and 14 Other Drugs — Reimbursement Pressure Ahead

Federal price negotiation for Botox signals potential downward pressure on reimbursement rates for therapeutic botulinum toxin in medspa and clinical settings.

Image: Inside MedSpa

Medicare has initiated price negotiation for Botox (onabotulinumtoxinA) and 14 other high-cost drugs, marking the first wave of federal price-setting authority under the Inflation Reduction Act. While Botox's primary medspa use is cosmetic (and thus not Medicare-reimbursed), the negotiation signals broader regulatory intent to constrain toxin pricing across all channels.

Medicare's Botox price negotiation signals potential downward pressure on manufacturer pricing across all channels, including medspa rebate programs.

For medspa practices, the real risk is indirect: if Medicare negotiates Botox prices downward, manufacturers may adjust wholesale pricing across all channels to maintain margin. This could compress the rebate programs (Alle, Aspire, Evolus Rewards) that practices rely on to optimize per-unit cost. Additionally, practices offering therapeutic botulinum toxin for migraine, hyperhidrosis, or spasticity under medical supervision should monitor reimbursement rates closely—Medicare's negotiated price will likely influence what commercial payers offer. The negotiation results are expected later this year; practices should prepare for potential margin pressure on both cosmetic and therapeutic toxin revenue.

Source: original report ↗

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $20/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Share

https://insidemedspa.com/article/medicare-negotiates-botox-price-14-drugs/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa Pro

    By the time it's news, it's too late.

    The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

    Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.
    The twice-a-week intelligence brief Go Pro · $20/mo